beta
Trial Radar IA
Lo studio clinico NCT05359991 (Project REACH) per Fibrosi cistica, Anemia falciforme, Infezione da SARS CoV 2 è in arruolamento. Consulti la vista a schede del Radar degli Studi Clinici e gli strumenti di scoperta IA per tutti i dettagli. Oppure, ponga pure una domanda qui.
Un studio corrisponde ai criteri del filtro
Vista a schede

Exercise in Child Health (Project REACH)

In arruolamento
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT05359991 (Project REACH) è uno studio interventistico per Fibrosi cistica, Anemia falciforme, Infezione da SARS CoV 2, attualmente in arruolamento. Avviato il 12 novembre 2020, prevede di arruolare 240 partecipanti. Sotto la guida di l'Università della California, Irvine, dovrebbe concludersi entro il 1 gennaio 2026. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 10 luglio 2025.
Sommario breve
This study is a cooperative investigation funded by the NIH. The project is a collaboration among three major NIH Clinical Translational Science Awardees: 1) UCI (lead site with its affiliate CHOC), 2) Northwestern University (with its affiliate Lurie Children's Hospital), and 3) USC (with its affiliate Children's Hospital of Los Angeles).

There is an increasing number of children who, through medical advances, now survive diseases and conditions that were once fatal, but which remain chronic and debilitating. A major challenge to improve both the immediate and long term care and health of such children has been the gap in our understanding of how to assess the biological effects of exercise. Like otherwise healthy children, children with chronic diseases and disabilities want to be physically active. The challenge is to determine what constitutes safe and beneficial level of physical activity when the underlying disease or condition [e.g., cystic fibrosis (CF) or sickle cell disease (SCD)] imposes physiological constraints on exercise that are not present in otherwise healthy children. Current exercise testing protocols were based on studies of athletes and high performing healthy individuals and were designed to test limits of performance at very high-intensity, unphysiological, maximal effort. These approaches are not optimal for children and adolescents with disease and disability. This project (REACH-Revamping Exercise Assessment in Child Health) is designed to address this gap. Cohorts of children will be identified with two major genetic diseases (CF and SCD) and measure exercise responses annually as they progress from early puberty to mid or late puberty over a 3-4year period. In addition, in the light of the pandemic, a group of children will be added who were affected by SARS-CoV-2 and investigate their responses to exercise. SARS-CoV-2 has similar long-term symptoms than CF and SCD have. Novel approaches to assessing physiological responses to exercise using advanced data analytics will be examined in relation to metrics of habitual physical activity, circulating biomarkers of inflammation and growth, leukocyte gene expression, and the impact of the underlying CF, SCD or SARS-CoV-2 condition. The data from this study will help to develop a toolkit of innovative metrics for exercise testing that will be made available to the research and clinical community.

Descrizione dettagliata
New, generalizable approaches are needed for measuring physical fitness and activity across a spectrum of pediatric health and disease.

Exercise in children and adolescents is not merely play but is an essential component of growth and development. Children are among the most spontaneously physically active human beings. It is not surprising that participation in PA (Physical Activity) is a major determinant of health across the lifespan and health-related quality of life in both healthy children and in children with chronic diseases. Despite this essential biologic role for PA, children have not been spared the relentless reduction in levels of PA that is creating a crisis in health care in our nation and throughout the world. Recognition of the enormous morbidity and cost of physical inactivity-related diseases, such as atherosclerosis, type 2 diabetes, and osteoporosis, has spurred new policy initiatives targeting preventive medicine early in life. The concept of pediatric origins of adult health and disease is gaining scientific merit, highlighting the need to transform existing notions of how to evaluate health in a growing child. A physically inactive (even normal weight) child may have no symptoms of disease, but evidence of deterioration in vascular health may already be present. As era of population health management and precision medicine are approaching, the notion of what it means to be a healthy child must change and include robust metrics of physical fitness.

Equally worrisome is that the deleterious health effects of physical inactivity and poor fitness are exacerbated in children with chronic disease and/or disabilities or with environmental-lifestyle conditions like obesity. Children with diseases or conditions previously associated with mortality during the first two decades of life (e.g., SCD, CF) are living longer due to remarkable advances in research and care, but are often unable to achieve levels of PA and fitness associated with health benefits in otherwise healthy children. Not surprisingly, the healthspan [the period of life free from serious chronic diseases and disability of children with chronic diseases is threatened not only by the underlying disease, but by the compounding effects of insufficient PA and sedentary behavior. Increasing PA and fitness is feasible, but has proven quite challenging to implement in a systematic manner. Once a pattern of physical inactivity and a sedentary lifestyle is established, a vicious cycle ensues, in which constraints on PA harm immediate health and contribute to lifelong health impairment ranging from cardiovascular and metabolic disease to osteoporosis. Exactly what constitutes ideal physical fitness in a child with a chronic condition remains unknown. Finding beneficial levels of PA in children with chronic disease or disability is challenging because the optimal range of exercise is much narrower than in a healthy child. Finally, as a result of the COVID-19 pandemic a sizable number of children are experiencing long-term effects such as fatigue, and will be included in our study. Similar to children with CF and SCD, studies of exercise and physical activity will provide insight into disease mechanisms and possible therapies.

Titolo ufficiale

Revamping Exercise Assessments in Child Health (Project REACH)

Condizioni
Fibrosi cisticaAnemia falciformeInfezione da SARS CoV 2
Pubblicazioni
Articoli scientifici e documenti di ricerca pubblicati su questo studio clinico:
Altri ID dello studio
  • Project REACH
  • 20195402
Numero NCT
Data di inizio (effettiva)
2020-11-12
Ultimo aggiornamento pubblicato
2025-07-10
Data di completamento (stimata)
2026-01
Arruolamento (previsto)
240
Tipo di studio
Interventistico
FASE
N.D.
Stato
In arruolamento
Scopo principale
Ricerca di base
Allocazione
Non randomizzato
Modello di intervento
In parallelo
Mascheramento
Nessuno (studio in aperto)
Bracci / Interventi
Gruppo/Braccio di partecipantiIntervento/Trattamento
Comparatore attivoHealthy Controls
Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in healthy controls. Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur: * The child will be in a fasted state. * An IV will be placed into the child's arm. * Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise.
Esercizio
Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables
SperimentaleChildren With Documented History of SARS CoV-2 Infection
Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in children with a documented history of SARS CoV-2 Infection. Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur: * The child will be in a fasted state. * An IV will be placed into the child's arm. * Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise.
Esercizio
Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables
SperimentaleChildren With Sickle Cell Disease (SCD)
Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in children with Children With Sickle Cell Disease (SCD). Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur: * The child will be in a fasted state. * An IV will be placed into the child's arm. * Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise.
Esercizio
Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables
SperimentaleChildren With Cystic Fibrosis (CF)
Cardiopulmonary Exercise Test (CPET) will be performed to measure cardiorespiratory responses in children with Children With Cystic Fibrosis (CF). Exercise will consist of up to 8, 2 minutes bouts of constant work rate cycle ergometry with 1 minute resting intervals between each exercise bout. A subgroup of children will be asked to allow the investigators to obtain blood samples during the exercise session. The following procedures will occur: * The child will be in a fasted state. * An IV will be placed into the child's arm. * Blood sampling will be taken at 4 time points; baseline, and the end of exercise, and at 30 and 60 minutes post exercise.
Esercizio
Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables
Esito primario
Misure di esitoDescrizione della misuraArco temporale
Gas Exchange Variables
oxygen uptake
8 Months
Whole Body Lean Mass
Measured by Dual X-Ray Densitometry
8 Months
Physical Activity
Measured by Actigraphy
8 Months
Biomarkers
IGF-1
8 Months
Gene Expression
Circulating leukocyte gene expression associated with exercise
8 Months
Gas Exchange Variables
V̇O2
8 Months
Gas Exchange Variables
Carbon dioxide output
8 Months
Gas Exchange Variables
V̇CO2
8 Months
Gas Exchange Variables
ventilation
8 Months
Gas Exchange Variables
V̇E
8 Months
Gas Exchange Variables
heart rate (HR)
8 Months
Fat Mass
Measured by Dual Energy X-Ray Absorptiometry
8 Months
% Body Fat
Measured by Dual X-Ray Densitometry
8 Months
Whole Body Bone Mineral Content
Measured by Dual X-Ray Densitometry
8 Months
Whole Body Bone Mineral Density
Measured by Dual X-Ray Densitometry
8 Months
Biomarkers
IL6
8 Months
Biomarkers
C-Reactive Protein
8 Months
Biomarkers
Glucose
8 Months
Biomarkers
insulin
8 Months
Biomarkers
lipid screen
8 Months
Biomarkers
lactate
8 Months
Biomarkers
CBC
8 Months
Gene Expression
Circulating Leukocyte Gene Expression Associated with Sickle Cell Anemia
8 Months
Gene Expression
Circulating Leukocyte Gene Expression Associated with Cystic Fibrosis
8 Months
Esito secondario
Misure di esitoDescrizione della misuraArco temporale
Behavioral responses to exercise
PROMIS Parent Fatigue Questionnaire
8 Months
Standardized assessments
TANNER Staging Questionnaire
8 Months
Behavioral responses to exercise
PROMIS Pediatric Fatigue Questionnaire
8 Months
Behavioral responses to exercise
Project REACH NHANES PAQ Adapted Questionnaire
8 Months
Behavioral responses to exercise
PEDSQL Fatigue Questionnaire
8 Months
Behavioral responses to exercise
Appendices Questionnaire
8 Months
Standardized assessments
Block Standardized FFQ
8 Months
Criteri di eleggibilità

Età idonea
Bambino
Età minima
10 Years
Sessi idonei
Tutti
Accetta volontari sani

Sickle Cell Disease

  • Tanner 1-5, corresponding approximately to ages 10-17 y/o
  • SCD diagnosis including all relevant genotypes
  • Determined to be in relatively good health as a patient with SCD with no complications from SCD that would render participation the study unadvisable
  • No evidence of other disease or disability that would impair participation in PA
  • Physician permission to perform CPET
  • BMI within the average range for age and condition

Cystic Fibrosis

  • Confirmed diagnosis of CF based on either two CF-causing mutations and/or a sweat chloride concentration of > 60 mmol/l after a positive newborn screening test or on two separate occasions
  • Tanner 1-5 corresponding approximately to ages 10-17 y/o as documented by a licensed independent provider at screening, or by a validated self-assessment tool
  • Determined to be in relatively good health as a patient with CF with no complications from CF that would render participation the study unadvisable as determined by a physician. Examples include history of submassive or massive hemoptysis or moderate to severe pulmonary hypertension.
  • BMI in the average range for age and condition
  • No evidence of other disease or disability that would impair participation in PA

Comparison (Healthy control)

  • Tanner 1-5 corresponding approximately to ages 10-17 y/o
  • Determined to be in good health by pre-participation history and physical examination performed by primary care providers or PERC staff
  • BMI and PA participation (by history) in the average range for age
  • No evidence of disease or disability that would impair participation in PA

Comparison (SARS-CoV-2)

  • Tanner 1-5 corresponding approximately to ages 10-17 y/o
  • Documented SARS-CoV-2 infection
  • Capable of doing exercise as determined by primary care providers or PERC a medical officer

Sickle Cell Disease Treatment for substance or alcohol abuse

  • Requiring chronic monthly transfusions
  • Other conditions that preclude exercise such as neuromotor disease, heart disease, or any other condition that would prevent a child from participating in PA

Cystic Fibrosis Treatment for substance or alcohol abuse

  • Other conditions that preclude exercise (such as neuromotor disease, heart disease, or any other condition that would prevent a child from participating in PA)
  • FEV1 < 40% predicted based on Global Lung Index equations
  • Current infection with Burkholderia cenocepacia or Mycobacterium abscessus

Comparison (Healthy control) Treatment for substance or alcohol abuse or chronic medication use • Determination by PERC staff of unsuitability for exercise

Comparison (SARS-CoV-2) Treatment for substance or alcohol abuse or chronic medication use

• Determination by PERC staff of unsuitability for exercise

University of California, Irvine logoUniversità della California, Irvine158 studi clinici attivi da esplorare
  • 🏥Children's Hospital of Orange County
  • 🏥Children's Hospital Los Angeles
  • 🏥Ann & Robert H Lurie Children's Hospital of Chicago
Parte responsabile dello studio
Dan Cooper, Investigatore principale, Professor, University of California, Irvine
Contatti principali dello studio
Contatto: Peter Horvath, Ph.D., (714) 456-8248, [email protected]
1 Centri dello studio in 1 paesi

California

University of California, Irvine, Irvine, California, 92697, United States
Shlomit Radom-Aizik, Ph.D., Contatto, (949) 824-2584, [email protected]
Dan Cooper, M.D., Contatto, (949) 824-1923, [email protected]
In arruolamento